IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Stock Overview
NASDAQ:IMCR - US45258D1054 - ADR
IMCR Key Statistics, Chart & Performance
The current stock price of IMCR is 32.59 USD. In the past month the price decreased by -3.98%. In the past year, price decreased by -9.17%.
IMCR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.6 | 366.65B | ||
| AMGN | AMGEN INC | 13.23 | 155.30B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 141.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.96 | 99.72B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.54 | 60.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.15B | ||
| ARGX | ARGENX SE - ADR | 73.07 | 41.45B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.25 | 36.69B | ||
| INSM | INSMED INC | N/A | 27.12B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.26B | ||
| NTRA | NATERA INC | N/A | 22.30B | ||
| BIIB | BIOGEN INC | 8.52 | 19.99B |
Related stock screener links
About IMCR
Company Profile
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. The company is headquartered in Abingdon, Oxfordshire and currently employs 493 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The firm has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
Company Info
IMMUNOCORE HOLDINGS PLC-ADR
90 Park Drive, Milton Park, Abingdon
Abingdon OXFORDSHIRE OX14 4RY GB
CEO: Bahija Jallal
Employees: 493
Phone: 441235438600
IMMUNOCORE HOLDINGS PLC-ADR / IMCR FAQ
What is the stock price of IMMUNOCORE HOLDINGS PLC-ADR today?
The current stock price of IMCR is 32.59 USD. The price decreased by -1.03% in the last trading session.
What is the ticker symbol for IMMUNOCORE HOLDINGS PLC-ADR stock?
The exchange symbol of IMMUNOCORE HOLDINGS PLC-ADR is IMCR and it is listed on the Nasdaq exchange.
On which exchange is IMCR stock listed?
IMCR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for IMMUNOCORE HOLDINGS PLC-ADR stock?
24 analysts have analysed IMCR and the average price target is 63.99 USD. This implies a price increase of 96.34% is expected in the next year compared to the current price of 32.59. Check the IMMUNOCORE HOLDINGS PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is IMMUNOCORE HOLDINGS PLC-ADR worth?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) has a market capitalization of 1.64B USD. This makes IMCR a Small Cap stock.
How many employees does IMMUNOCORE HOLDINGS PLC-ADR have?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) currently has 493 employees.
What are the support and resistance levels for IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) has a support level at 31.96 and a resistance level at 32.61. Check the full technical report for a detailed analysis of IMCR support and resistance levels.
Is IMMUNOCORE HOLDINGS PLC-ADR (IMCR) expected to grow?
The Revenue of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) is expected to grow by 27.2% in the next year. Check the estimates tab for more information on the IMCR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMCR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMCR, evaluating the profitability, health, valuation and growth aspects
- IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Sales and EPS estimates to see what analysts future expectations are.
- IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Stock Chart to make your own analysis
- IMMUNOCORE HOLDINGS PLC-ADR (IMCR) Latest news and press-releases to stay up to date.
Does IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock pay dividends?
IMCR does not pay a dividend.
When does IMMUNOCORE HOLDINGS PLC-ADR (IMCR) report earnings?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) will report earnings on 2025-11-04, before the market open.
What is the Price/Earnings (PE) ratio of IMMUNOCORE HOLDINGS PLC-ADR (IMCR)?
IMMUNOCORE HOLDINGS PLC-ADR (IMCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
What is the Short Interest ratio of IMMUNOCORE HOLDINGS PLC-ADR (IMCR) stock?
The outstanding short interest for IMMUNOCORE HOLDINGS PLC-ADR (IMCR) is 18.38% of its float. Check the ownership tab for more information on the IMCR short interest.
IMCR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IMCR. When comparing the yearly performance of all stocks, IMCR is a bad performer in the overall market: 83.5% of all stocks are doing better.
IMCR Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to IMCR. IMCR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
IMCR Financial Highlights
Over the last trailing twelve months IMCR reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 62.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.88% | ||
| ROE | -5.23% | ||
| Debt/Equity | 1.01 |
IMCR Forecast & Estimates
24 analysts have analysed IMCR and the average price target is 63.99 USD. This implies a price increase of 96.34% is expected in the next year compared to the current price of 32.59.
For the next year, analysts expect an EPS growth of 20.54% and a revenue growth 27.2% for IMCR